Extravascular fibrinogen in the white matter of Alzheimer’s disease and normal aged brains

implications for fibrinogen as a biomarker for Alzheimer’s disease

Kirsty E. McAleese, Sophie Graham, Madhurima Dey, Lauren Walker, Daniel Erskine, Mary Johnson, Eleanor Johnston, Alan J. Thomas, Ian G. McKeith, Charles DeCarli, Johannes Attems

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The blood–brain barrier (BBB) regulates cerebrovascular permeability and leakage of blood-derived fibrinogen. Dysfunction of the BBB has been associated with cerebral arteriolosclerosis small vessel disease (SVD) and white matter lesions (WML). Furthermore, BBB dysfunction is associated with the pathogenesis of Alzheimer’s disease (AD) with the presence of CSF plasma proteins suggested to be a potential biomarker of AD. We aimed to determine if extravascular fibrinogen in the white matter was associated with the development of AD hallmark pathologies, i.e., hyperphosphorylated tau (HPτ) and amyloid-β (Aβ), as well as SVD, cerebral amyloid angiopathy (CAA) and measures of white matter damage. Using human post-mortem brains, parietal tissue from 20 AD and 22 non-demented controls was quantitatively assessed for HPτ, Aβ, white matter damage severity, axonal density, demyelination and the burden of extravascular fibrinogen in both WML and normal appearing white matter (NAWM). SVD severity was determined by calculating sclerotic indices. WML- and NAWM fibrinogen burden was not significantly different between AD and controls nor was it associated with the burden of HPτ or Aβ pathology, or any measures of white matter damage. Increasing severity of SVD was associated with and a predictor of both higher WML- and NAWM fibrinogen burden (all P < 0.05) in controls only. In cases with minimal SVD NAWM fibrinogen burden was significantly higher in the AD cases (P < 0.05). BBB dysfunction was present in both non-demented and AD brains and was not associated with the burden of AD-associated cortical pathologies. BBB dysfunction was strongly associated with SVD but only in the non-demented controls. In cases with minimal SVD, BBB dysfunction was significantly worse in AD cases possibly indicating the influence of CAA. In conclusion, extravascular fibrinogen is not associated with AD hallmark pathologies but indicates SVD, suggesting that the presence of fibrinogen in the CSF is not a surrogate marker for AD pathology.

Original languageEnglish (US)
JournalBrain Pathology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Leukoencephalopathies
Fibrinogen
Alzheimer Disease
Biomarkers
Brain
Pathology
Cerebral Amyloid Angiopathy
White Matter
Arteriolosclerosis
Cerebral Small Vessel Diseases
Demyelinating Diseases
Amyloid
Blood Proteins
Permeability

Keywords

  • Alzheimer’s disease
  • biomarker
  • blood–brain barrier
  • cerebral small vessel disease
  • fibrinogen
  • white matter hyperintensities
  • white matter lesion

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

Extravascular fibrinogen in the white matter of Alzheimer’s disease and normal aged brains : implications for fibrinogen as a biomarker for Alzheimer’s disease. / McAleese, Kirsty E.; Graham, Sophie; Dey, Madhurima; Walker, Lauren; Erskine, Daniel; Johnson, Mary; Johnston, Eleanor; Thomas, Alan J.; McKeith, Ian G.; DeCarli, Charles; Attems, Johannes.

In: Brain Pathology, 01.01.2019.

Research output: Contribution to journalArticle

McAleese, Kirsty E. ; Graham, Sophie ; Dey, Madhurima ; Walker, Lauren ; Erskine, Daniel ; Johnson, Mary ; Johnston, Eleanor ; Thomas, Alan J. ; McKeith, Ian G. ; DeCarli, Charles ; Attems, Johannes. / Extravascular fibrinogen in the white matter of Alzheimer’s disease and normal aged brains : implications for fibrinogen as a biomarker for Alzheimer’s disease. In: Brain Pathology. 2019.
@article{1a599e1b95454e2984257fb548061c90,
title = "Extravascular fibrinogen in the white matter of Alzheimer’s disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer’s disease",
abstract = "The blood–brain barrier (BBB) regulates cerebrovascular permeability and leakage of blood-derived fibrinogen. Dysfunction of the BBB has been associated with cerebral arteriolosclerosis small vessel disease (SVD) and white matter lesions (WML). Furthermore, BBB dysfunction is associated with the pathogenesis of Alzheimer’s disease (AD) with the presence of CSF plasma proteins suggested to be a potential biomarker of AD. We aimed to determine if extravascular fibrinogen in the white matter was associated with the development of AD hallmark pathologies, i.e., hyperphosphorylated tau (HPτ) and amyloid-β (Aβ), as well as SVD, cerebral amyloid angiopathy (CAA) and measures of white matter damage. Using human post-mortem brains, parietal tissue from 20 AD and 22 non-demented controls was quantitatively assessed for HPτ, Aβ, white matter damage severity, axonal density, demyelination and the burden of extravascular fibrinogen in both WML and normal appearing white matter (NAWM). SVD severity was determined by calculating sclerotic indices. WML- and NAWM fibrinogen burden was not significantly different between AD and controls nor was it associated with the burden of HPτ or Aβ pathology, or any measures of white matter damage. Increasing severity of SVD was associated with and a predictor of both higher WML- and NAWM fibrinogen burden (all P < 0.05) in controls only. In cases with minimal SVD NAWM fibrinogen burden was significantly higher in the AD cases (P < 0.05). BBB dysfunction was present in both non-demented and AD brains and was not associated with the burden of AD-associated cortical pathologies. BBB dysfunction was strongly associated with SVD but only in the non-demented controls. In cases with minimal SVD, BBB dysfunction was significantly worse in AD cases possibly indicating the influence of CAA. In conclusion, extravascular fibrinogen is not associated with AD hallmark pathologies but indicates SVD, suggesting that the presence of fibrinogen in the CSF is not a surrogate marker for AD pathology.",
keywords = "Alzheimer’s disease, biomarker, blood–brain barrier, cerebral small vessel disease, fibrinogen, white matter hyperintensities, white matter lesion",
author = "McAleese, {Kirsty E.} and Sophie Graham and Madhurima Dey and Lauren Walker and Daniel Erskine and Mary Johnson and Eleanor Johnston and Thomas, {Alan J.} and McKeith, {Ian G.} and Charles DeCarli and Johannes Attems",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bpa.12685",
language = "English (US)",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Extravascular fibrinogen in the white matter of Alzheimer’s disease and normal aged brains

T2 - implications for fibrinogen as a biomarker for Alzheimer’s disease

AU - McAleese, Kirsty E.

AU - Graham, Sophie

AU - Dey, Madhurima

AU - Walker, Lauren

AU - Erskine, Daniel

AU - Johnson, Mary

AU - Johnston, Eleanor

AU - Thomas, Alan J.

AU - McKeith, Ian G.

AU - DeCarli, Charles

AU - Attems, Johannes

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The blood–brain barrier (BBB) regulates cerebrovascular permeability and leakage of blood-derived fibrinogen. Dysfunction of the BBB has been associated with cerebral arteriolosclerosis small vessel disease (SVD) and white matter lesions (WML). Furthermore, BBB dysfunction is associated with the pathogenesis of Alzheimer’s disease (AD) with the presence of CSF plasma proteins suggested to be a potential biomarker of AD. We aimed to determine if extravascular fibrinogen in the white matter was associated with the development of AD hallmark pathologies, i.e., hyperphosphorylated tau (HPτ) and amyloid-β (Aβ), as well as SVD, cerebral amyloid angiopathy (CAA) and measures of white matter damage. Using human post-mortem brains, parietal tissue from 20 AD and 22 non-demented controls was quantitatively assessed for HPτ, Aβ, white matter damage severity, axonal density, demyelination and the burden of extravascular fibrinogen in both WML and normal appearing white matter (NAWM). SVD severity was determined by calculating sclerotic indices. WML- and NAWM fibrinogen burden was not significantly different between AD and controls nor was it associated with the burden of HPτ or Aβ pathology, or any measures of white matter damage. Increasing severity of SVD was associated with and a predictor of both higher WML- and NAWM fibrinogen burden (all P < 0.05) in controls only. In cases with minimal SVD NAWM fibrinogen burden was significantly higher in the AD cases (P < 0.05). BBB dysfunction was present in both non-demented and AD brains and was not associated with the burden of AD-associated cortical pathologies. BBB dysfunction was strongly associated with SVD but only in the non-demented controls. In cases with minimal SVD, BBB dysfunction was significantly worse in AD cases possibly indicating the influence of CAA. In conclusion, extravascular fibrinogen is not associated with AD hallmark pathologies but indicates SVD, suggesting that the presence of fibrinogen in the CSF is not a surrogate marker for AD pathology.

AB - The blood–brain barrier (BBB) regulates cerebrovascular permeability and leakage of blood-derived fibrinogen. Dysfunction of the BBB has been associated with cerebral arteriolosclerosis small vessel disease (SVD) and white matter lesions (WML). Furthermore, BBB dysfunction is associated with the pathogenesis of Alzheimer’s disease (AD) with the presence of CSF plasma proteins suggested to be a potential biomarker of AD. We aimed to determine if extravascular fibrinogen in the white matter was associated with the development of AD hallmark pathologies, i.e., hyperphosphorylated tau (HPτ) and amyloid-β (Aβ), as well as SVD, cerebral amyloid angiopathy (CAA) and measures of white matter damage. Using human post-mortem brains, parietal tissue from 20 AD and 22 non-demented controls was quantitatively assessed for HPτ, Aβ, white matter damage severity, axonal density, demyelination and the burden of extravascular fibrinogen in both WML and normal appearing white matter (NAWM). SVD severity was determined by calculating sclerotic indices. WML- and NAWM fibrinogen burden was not significantly different between AD and controls nor was it associated with the burden of HPτ or Aβ pathology, or any measures of white matter damage. Increasing severity of SVD was associated with and a predictor of both higher WML- and NAWM fibrinogen burden (all P < 0.05) in controls only. In cases with minimal SVD NAWM fibrinogen burden was significantly higher in the AD cases (P < 0.05). BBB dysfunction was present in both non-demented and AD brains and was not associated with the burden of AD-associated cortical pathologies. BBB dysfunction was strongly associated with SVD but only in the non-demented controls. In cases with minimal SVD, BBB dysfunction was significantly worse in AD cases possibly indicating the influence of CAA. In conclusion, extravascular fibrinogen is not associated with AD hallmark pathologies but indicates SVD, suggesting that the presence of fibrinogen in the CSF is not a surrogate marker for AD pathology.

KW - Alzheimer’s disease

KW - biomarker

KW - blood–brain barrier

KW - cerebral small vessel disease

KW - fibrinogen

KW - white matter hyperintensities

KW - white matter lesion

UR - http://www.scopus.com/inward/record.url?scp=85060754294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060754294&partnerID=8YFLogxK

U2 - 10.1111/bpa.12685

DO - 10.1111/bpa.12685

M3 - Article

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

ER -